hypogonadism; trt; fda; health

Following the FDA’s announcement on a potential pathway to expand testosterone replacement therapy (TRT) labeling,1 leading experts in men’s health shared their perspectives on what this development could mean for patients and clinical practice.

https://www.ajmc.com/view/fda-signals-potential-expansion-of-testosterone-therapy-to-treat-low-libido-in-idiopathic-hypogonadism https://www.fda.gov/news-events/press-announcements/fda-takes-step-forward-testosterone-therapy-men The U.S. Food and Drug Administration today is taking an...